Cargando…

Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies

Missense mutations in LRRK2 (leucine-rich repeat kinase 2) are a major cause of PD (Parkinson's disease). Several antibodies against LRRK2 have been developed, but results using these polyclonal antibodies have varied widely leading to conflicting conclusions. To address this challenge, the Mic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Paul, Hinkle, Kelly M., Sukar, Nour N., Sepulveda, Bryan, Mesias, Roxana, Serrano, Geidy, Alessi, Dario R., Beach, Thomas G., Benson, Deanna L., White, Charles L., Cowell, Rita M., Das, Sonal S., West, Andrew B., Melrose, Heather L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682752/ https://www.ncbi.nlm.nih.gov/pubmed/23560750 http://dx.doi.org/10.1042/BJ20121742

Ejemplares similares

Short- and Long-Term Effects of LRRK2 on Axon and Dendrite Growth
por: Sepulveda, Bryan, et al.
Publicado: (2013)

Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia
por: Maekawa, Tatsunori, et al.
Publicado: (2016)

Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010)

LRRK2 and ubiquitination: implications for kinase inhibitor therapy
por: Melrose, Heather L.
Publicado: (2015)

Identification and Characterization of a Leucine-Rich Repeat Kinase 2 (LRRK2) Consensus Phosphorylation Motif
por: Pungaliya, Pooja P., et al.
Publicado: (2010)

Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity
por: Fernández, Belén, et al.
Publicado: (2022)

Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson’s disease and beyond
por: Bae, Jae Ryul, et al.
Publicado: (2015)

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)
por: Konstantinidou, Markella, et al.
Publicado: (2020)

Dynamic and redundant regulation of LRRK2 and LRRK1 expression
por: Biskup, Saskia, et al.
Publicado: (2007)

Origins of Parkinson’s Disease in Brain Development: Insights From Early and Persistent Effects of LRRK2-G2019S on Striatal Circuits
por: Huntley, George W., et al.
Publicado: (2020)

Leucine‐rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes
por: Mercatelli, Daniela, et al.
Publicado: (2019)

A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
por: Vissers, Maurits F. J. M., et al.
Publicado: (2023)

LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
por: Bliederhaeuser, Corinna, et al.
Publicado: (2016)

Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms
por: Malik, Asad U., et al.
Publicado: (2021)

Leucine-Rich Repeat Kinase 2 (Lrrk2)-Sensitive Na(+)/K(+) ATPase Activity in Dendritic Cells
por: Hosseinzadeh, Zohreh, et al.
Publicado: (2017)

Leucine-rich repeat kinase-2 (LRRK2) modulates paraquat-induced inflammatory sickness and stress phenotype
por: Rudyk, Chris, et al.
Publicado: (2019)

LRRK2 phosphorylates novel tau epitopes and promotes tauopathy
por: Bailey, Rachel M., et al.
Publicado: (2013)

Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs
por: Baptista, Marco A. S., et al.
Publicado: (2013)

Interplay between Leucine-Rich Repeat Kinase 2 (LRRK2) and p62/SQSTM-1 in Selective Autophagy
por: Park, Sangwook, et al.
Publicado: (2016)

Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers
por: Wang, Shijie, et al.
Publicado: (2017)

Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity
por: Kluss, Jillian H., et al.
Publicado: (2018)

Impact of Type II LRRK2 inhibitors on signaling and mitophagy
por: Tasegian, Anna, et al.
Publicado: (2021)

Generation of fourteen isogenic cell lines for Parkinson’s disease-associated leucine-rich repeat kinase (LRRK2)
por: Beylina, Aleksandra, et al.
Publicado: (2021)

Expression Analysis of Lrrk1, Lrrk2 and Lrrk2 Splice Variants in Mice
por: Giesert, Florian, et al.
Publicado: (2013)

The Parkinson’s disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4
por: Funk, Natalja, et al.
Publicado: (2019)

Leucine-rich repeat kinase LRRK1 regulates endosomal trafficking of the EGF receptor
por: Hanafusa, Hiroshi, et al.
Publicado: (2011)

Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics
por: Kelly, Kaela, et al.
Publicado: (2020)

LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors
por: Hinkle, Kelly M, et al.
Publicado: (2012)

Crystal structure of the WD40 domain dimer of LRRK2
por: Zhang, Pengfei, et al.
Publicado: (2019)

LrrkA, a kinase with leucine‐rich repeats, links folate sensing with Kil2 activity and intracellular killing
por: Bodinier, Romain, et al.
Publicado: (2019)

Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
por: Ness, Daniel, et al.
Publicado: (2013)

Leucine-Rich Repeat Kinase 2 (Lrrk2) Deficiency Diminishes the Development of Experimental Autoimmune Uveitis (EAU) and the Adaptive Immune Response
por: Wandu, Wambui S., et al.
Publicado: (2015)

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
por: Lobbestael, E., et al.
Publicado: (2016)

LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding
por: Taymans, Jean-Marc, et al.
Publicado: (2011)

Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases
por: Gomez, Rachel C., et al.
Publicado: (2019)

Exosome markers of LRRK2 kinase inhibition
por: Wang, Shijie, et al.
Publicado: (2020)

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease
por: Gonzalez-Hunt, C. P., et al.
Publicado: (2020)

Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression
por: Ho, Dong Hwan, et al.
Publicado: (2015)

Leucine-Rich Repeat Kinase 2 (LRRK2) Stimulates IL-1β-Mediated Inflammatory Signaling through Phosphorylation of RCAN1
por: Han, Kyung A., et al.
Publicado: (2017)

Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization
por: Pathak, Pragya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_afdkiv2k8nvskrvfi0i6qq4be2